All In Biotech

Drug Trial Radar · NCT07591298

Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia

A Multicenter, Open-label Phase II Clinical Trial Evaluating the Efficacy and Safety of SYH2070 Injection in Chinese Participants With Homozygous Familial Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

May 24, 2026

Primary completion

Sep 16, 2027

Study completion Sep 30, 2027

Sponsor

Sponsor type
Industry
First posted
May 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multicenter, open-label, phase II clinical study, aiming to evaluate the efficacy and safety of SYH2070 injection in participants with HoFH.

Conditions

  • Diagnosed With HoFH

Interventions

  • SYH2070 injection dose1Drug

    The patient will receive a treatment period of 48weeks

  • SYH2070 injection dose2Drug

    The patient will receive a treatment period of 48weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage change in serum LDL-C level from baselineTime frame: week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Xiangya Hospital

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.